RxDoctor Payments Data

Kevin Prendiville, MD

Ophthalmology · Dana Point, CANPI 1588636765

Payments from drug & device makers

$8,229in general payments, 2019–2025

Across 218 payments — averaging $37.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Ivantis, Inc$1K
  • Rxsight Inc$1K
  • Sight Sciences, Inc.$721
  • Dompe US, Inc.$506
  • AbbVie$486
  • plus $2K from 12 others

What the payments were for

  • Consulting fees$5006%
  • Speaking & faculty fees$390%
  • Food & beverage$7,57892%
  • Education$681%
  • Gifts$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,229 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$838,155
Medicare patients
1,208
Services billed
4,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate412$17,471
RestasisCyclosporine13$10,309
RhopressaNetarsudil Mesylate20$6,135
Latanoprost358$4,789
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat140$2,733
Timolol Maleate62$993
Brimonidine Tartrate30$827
Ofloxacin44$526
ErythromycinErythromycin Base52$466
Ketorolac Tromethamine14$446
MoxifloxacinMoxifloxacin Hcl17$388
Dorzolamide Hcl14$294
Doxycycline Hyclate13$249
Acetazolamide16$202
Prednisone12$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$486$10,30913 claims
Aerie Pharmaceuticals, Inc.Rhopressa$327$6,13520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Dana Point

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →